Related Experiment Video

Updated: Jan 3, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

691

MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities

Yajuan Xiao1,2, Brock Humphries3, Chengfeng Yang1

  • 1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.

Non-Coding RNA
|November 23, 2019
PubMed

Insights

MicroRNA-205-5p (miR-205) acts as a tumor suppressor in breast cancer, inhibiting growth and metastasis. Its downregulation suggests potential as a diagnostic biomarker and therapeutic target, especially for triple-negative breast cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.
  • Dysregulated miRNAs are implicated in cancer development and progression.
  • miR-205-5p is often downregulated in breast cancer, suggesting a tumor-suppressive role.

Purpose of the Study:

  • To review the role of miR-205-5p dysregulation in various breast cancer subtypes.
  • To discuss miR-205-5p's impact on breast cancer proliferation, EMT, metastasis, stemness, and therapy resistance.
  • To explore regulatory mechanisms and the diagnostic/therapeutic potential of miR-205-5p.

Main Methods:

  • Literature review of studies on miR-205-5p in breast cancer.
  • Analysis of validated miR-205-5p direct targets.
  • Synthesis of findings on miR-205-5p's function and regulation.

Main Results:

  • miR-205-5p exhibits tumor-suppressive functions in breast cancer.
  • Downregulation of miR-205-5p is linked to increased proliferation, EMT, metastasis, and therapy resistance.
  • Genetic and epigenetic factors influence miR-205-5p expression in breast cancer.

Conclusions:

  • miR-205-5p is a crucial tumor suppressor inhibiting breast cancer growth and metastasis, particularly in triple-negative breast cancer.
  • miR-205-5p holds promise as a diagnostic biomarker and therapeutic target for metastatic breast cancer.
Keywords:
Her2+ breast cancerbreast cancerluminal A/B breast cancermetastatic breast cancermiR-205-5p (miR-205)triple negative breast cancer

More Related Videos

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K